Zosia Piotrowska, MD, MHS

Articles

MARIPOSA Study Insights

July 16th 2024

Benjamin Levy, MD, initiates a discussion on the rationale behind using amivantamab and lazertinib as a first-line treatment for EGFR-mutant non-small cell lung cancer and reviews the recently presented efficacy and safety data from the MARIPOSA trial.

Osimertinib Monotherapy vs. Combination Therapy: Patient Selection in EGFR-Mutant Advanced NSCLC

July 16th 2024

The panel discusses which patients with EGFR-mutant non-small cell lung cancer (NSCLC) are more likely to receive frontline treatment with either osimertinib monotherapy or the combination of osimertinib and chemotherapy, based on individual patient characteristics and preferences.

Advancing Treatment for EGFR-Mutant Advanced NSCLC: Lessons from FLAURA2

July 8th 2024

Helena A. Yu, MD, discusses her treatment strategy for patients with EGFR-mutant non-small cell lung cancer (NSCLC), emphasizing current guidelines and standard of care, while Zosia Piotrowska, MD, MHS, examines the key efficacy and safety findings from the FLAURA2 study, which evaluated first-line osimertinib combined with chemotherapy in patients with advanced EGFR-mutant NSCLC.

Navigating Between ADCs in NSCLC

July 8th 2024

The panel examines the characteristics of patients with non-small cell lung cancer (NSCLC) without actionable alterations who might be the best candidates for frontline treatment with either sacituzumab govitecan or datopotamab deruxtecan (Dato-DXd) and identifies the persisting unmet needs for this patient population.

Exploring Dato-DXd Combinations as First-Line Therapy for Advanced NSCLC

July 2nd 2024

Julia Rotow, MD, explores the rationale, study design, and primary endpoints of the AVANZAR trial, which investigated the combination of datopotamab deruxtecan (Dato-DXd), durvalumab, and carboplatin as a first-line treatment for patients with advanced non-small cell lung cancer lacking actionable mutations, and discusses the patient population most likely to benefit from this drug combination.

Exploring the TROPION-Lung04 Study

July 2nd 2024

Benjamin Levy, MD, presents an overview of the TROPION-Lung04 study in the first-line setting, focusing on the toxicity profile and potential impact on clinical practice.

Role of Antibody-Drug Conjugates in NSCLC Treatment: Insights from EVOKE-02

June 24th 2024

Benjamin Levy, MD, leads discussion on the promising potential of antibody-drug conjugates (ADCs) in treating non-small cell lung cancer (NSCLC) with non-actionable mutations, while Helena A. Yu, MD, presents an overview of the EVOKE-02 study, emphasizing key efficacy and safety data that could significantly impact the current treatment landscape.

Treatment Strategies for NSCLC with Non-Actionable Mutations

June 24th 2024

Mark Socinski, MD; Helena A. Yu, MD; Zosia Piotrowska, MD, MHS; Julia Rotow, MD; and Benjamin Levy, MD, provide a concise overview of current first-line treatment options for non-small cell lung cancer (NSCLC), including their approaches for NSCLC with non-actionable mutations and the influence of PD-L1 tumor proportion score status on treatment choices.